A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 2, 2011, Pages 102-112

  Zheng, Zhenfeng ^a   Shi, Huilan ^a   Jia, Junya ^a   Li, Dong ^a   Lin, Shan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Aliskiren; angiotensin receptor blocker; direct rennin inhibitor; hypertension; meta analysis

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; VALSARTAN;

ARTICLE; BACKACHE; BLOOD PRESSURE REGULATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; INFECTION; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION;

EID: 79958075448     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310381912     Document Type: Article

References (28)

1. Dzau VJ Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001 ; 37: 1047-1052. (Pubitemid 32304002)
2. Maibaum J. and Feldman DL Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Patents 2003 ; 13: 589-603. (Pubitemid 36622214)
3. Zaman MA, Oparil S. and Calhou DA Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002 ; 1: 621-636. (Pubitemid 37368827)
4. Ruggenenti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999 ; 354: 359-364. (Pubitemid 29355751)
5. Flather MD, Yusuf S., Køber L., Pfeffer M., Hall A., Murray G., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000 ; 355: 1575-1581. (Pubitemid 30240501)
6. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003 ; 362: 1527-1535. (Pubitemid 37410190)
7. Watanabe T., Barker TA and Berk BC Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005 ; 45: 163-169. (Pubitemid 40179951)
8. Skeggs LT Jr, Kahn JR, Lentz K. and Shumway NP The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957 ; 106: 439-453.
9. Gross F., Lazar J. and Orth H. Inhibition of the renin-angiotensinogen reaction by pepstatin. Science 1971 ; 175: 656.
10. Wood JM, Maibaum J., Rahuel J., Grütter MG, Cohen NC, Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 ; 308: 698-705. (Pubitemid 36976519)
11. Moher D., Cook DJ, Eastwood S., Olkin I., Rennie D. and Stroup DF Improving the quality of reports of meta-analysis of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analysis. Lancet 1999 ; 354: 1896-1900.
12. Landis JR and Koch GG The measurement of observer agreement for categorical data. Biometrics 1977 ; 33: 159-174. (Pubitemid 8054849)
13. Jadad AR, Moore RA, Carroll D., Jenkinson C., Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 ; 17: 1-12. (Pubitemid 26120810)
14. Higgins JP, Thompson SG, Deeks JJ and Altman DG Measuring inconsistency in meta-analysis. Br Med J 2003 ; 327: 557-560.
15. Egger M., Davey Smith G., Schneider M. and Minder C. Bias in the meta-analysis detected by a simple, graphical test. Br Med J 1997 ; 315: 629-634. (Pubitemid 27387172)
16. Stanton A., Jensen C., Nussberger J. and O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003 ; 42: 1137-1143. (Pubitemid 37549068)
17. Gradman AH, Schmieder RE, Lins RL, Nussberger J., Chiang Y. and Bedigian MP Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 ; 111: 1012-1018. (Pubitemid 40354519)
18. Jordan J., Engeli S., Boye SW, Le Breton S. and Keefe DL Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007 ; 49: 1047-1055. (Pubitemid 351664315)
19. Oparil S., Yarows SA, Patel S., Fang H., Zhang J. and Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007 ; 370: 221-229. (Pubitemid 47069535)
20. Pool JL, Schmieder RE, Azizi M., Aldigier JC, Januszewicz A., Zidek W., et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007 ; 20: 11-20. (Pubitemid 46014059)
21. Yarows SA, Oparil S., Patel S., Fang H. and Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008 ; 25: 1288-1302.
22. Geiger H., Barranco E., Gorostidi M., Taylor A., Zhang X., Xiang Z., et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens (Greenwich) 2009 ; 11: 324-332.
23. Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J. and Tou CK Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) 2004 ; 6: 485-493.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 ; 289: 2560-2572. (Pubitemid 37430158)
25. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hpertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 ; 25: 1105-1187. (Pubitemid 46924065)
26. Neutel JM, Smith DH and Weber MA Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001 ; 12: 286-292. (Pubitemid 32202714)
27. The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008 ; 358: 1547-1559.
28. Parving HH, Persson F., Lewis JB, Lewis EJ, Hollenberg NK and AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 ; 358: 2433-2446. (Pubitemid 351793017)